{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:02:05Z","timestamp":1794614525966,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-026-07441-x","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:45:35Z","timestamp":1785469535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed methotrexate toxicity after initial clearance in a critically ill patient with severe fluid overload"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2127-9226","authenticated-orcid":false,"given":"April","family":"Slamowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron M.","family":"Fedida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"LaPlante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"12","key":"7441_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382.","journal-title":"Oncologist"},{"issue":"1","key":"7441_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52\u201361.","journal-title":"Oncologist"},{"issue":"4","key":"7441_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.08030621","volume":"17","author":"M Ghannoum","year":"2022","unstructured":"Ghannoum M, et al. Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin J Am Soc Nephrol. 2022;17(4):602\u201322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"7441_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1592\/phco.30.1.111","volume":"30","author":"AM Vilay","year":"2010","unstructured":"Vilay AM, et al. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase. Pharmacotherapy. 2010;30(1):111.","journal-title":"Pharmacotherapy"},{"key":"7441_CR5","doi-asserted-by":"publisher","first-page":"1495705","DOI":"10.3389\/fmed.2025.1495705","volume":"12","author":"ACN Tome","year":"2025","unstructured":"Tome ACN, et al. High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights. Front Med (Lausanne). 2025;12:1495705.","journal-title":"Front Med (Lausanne)"},{"key":"7441_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/CEOR.S397154","volume":"15","author":"J Kala","year":"2023","unstructured":"Kala J, et al. Glucarpidase for treating adults with delayed methotrexate elimination due to impaired renal function: an economic simulation analysis. Clinicoecon Outcomes Res. 2023;15:165\u201379.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"7441_CR7","first-page":"e202410510","volume":"123","author":"L Queizan","year":"2025","unstructured":"Queizan L, et al. Severe nephrotoxicity during high-dose methotrexate administration in an adolescent with acute lymphoblastic leukemia. Arch Argent Pediatr. 2025;123(4):e202410510.","journal-title":"Arch Argent Pediatr"},{"issue":"11","key":"7441_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ccr3.302","volume":"3","author":"A Reshetnik","year":"2015","unstructured":"Reshetnik A, et al. High-flux hemodialysis after administering high-dose methotrexate in a patient with posttransplant lymphoproliferative disease and impaired renal function. Clin Case Rep. 2015;3(11):932\u20136.","journal-title":"Clin Case Rep"},{"issue":"12","key":"7441_CR9","first-page":"3487","volume":"34","author":"SH Wan","year":"1974","unstructured":"Wan SH, et al. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res. 1974;34(12):3487\u201391.","journal-title":"Cancer Res"},{"issue":"2","key":"7441_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00280-004-0797-y","volume":"54","author":"JL Pauley","year":"2004","unstructured":"Pauley JL, et al. Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol. 2004;54(2):146\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"7441_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00280-002-0512-9","volume":"50","author":"J Li","year":"2002","unstructured":"Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol. 2002;50(5):373\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"7441_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","volume":"28","author":"SM Wall","year":"1996","unstructured":"Wall SM, et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28(6):846\u201354.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"7441_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1177\/10781552211052564","volume":"28","author":"R Sakran","year":"2022","unstructured":"Sakran R, et al. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury. J Oncol Pharm Pract. 2022;28(2):508\u201315.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"7441_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s12882-020-02145-5","volume":"21","author":"S Liu","year":"2020","unstructured":"Liu S, et al. Effect of changing treatment to high-flux hemodialysis (HFHD) on mortality in patients with long-term low flux hemodialysis (LFHD): a propensity score matched cohort study. BMC Nephrol. 2020;21(1):485.","journal-title":"BMC Nephrol"},{"issue":"10","key":"7441_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00467-002-0946-7","volume":"17","author":"JM Saland","year":"2002","unstructured":"Saland JM, et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002;17(10):825\u20139.","journal-title":"Pediatr Nephrol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07441-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07441-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07441-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:22:49Z","timestamp":1792160569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07441-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7441"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-07441-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10009170\/v1","asserted-by":"object"}]},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent to publish the information has been granted by the guardians of the patient. Ethics approval was not necessary for a case report.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent to publish the information has been granted by the guardians of the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1009"}}